Carnegie Capital Asset Management LLC Has $714,000 Stake in Steris Plc (STE)
Carnegie Capital Asset Management LLC grew its stake in shares of Steris Plc (NYSE:STE) by 0.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,685 shares of the medical equipment provider’s stock after buying an additional 2 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Steris Plc were worth $714,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Citigroup Inc. purchased a new position in shares of Steris Plc during the 2nd quarter valued at about $206,000. Van Cleef Asset Management Inc purchased a new position in shares of Steris Plc during the 2nd quarter valued at about $208,000. Cigna Investments Inc. New purchased a new position in shares of Steris Plc during the 2nd quarter valued at about $209,000. BT Investment Management Ltd purchased a new position in shares of Steris Plc during the 2nd quarter valued at about $210,000. Finally, Aureus Asset Management LLC purchased a new position in shares of Steris Plc during the 1st quarter valued at about $245,000. 93.33% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Steris Plc (NYSE STE) traded up 0.84% during mid-day trading on Friday, reaching $88.40. The company had a trading volume of 454,727 shares. The company has a market capitalization of $7.53 billion, a price-to-earnings ratio of 63.23 and a beta of 1.29. The stock has a 50 day moving average of $85.66 and a 200-day moving average of $78.30. Steris Plc has a 52 week low of $63.80 and a 52 week high of $88.43.
Steris Plc (NYSE:STE) last issued its earnings results on Tuesday, August 8th. The medical equipment provider reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.05. Steris Plc had a return on equity of 11.39% and a net margin of 4.63%. The firm had revenue of $608.00 million for the quarter, compared to the consensus estimate of $597.66 million. During the same quarter in the prior year, the business earned $0.79 earnings per share. The company’s revenue was down 4.8% compared to the same quarter last year. On average, analysts expect that Steris Plc will post $4.06 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Tuesday, August 29th were paid a $0.31 dividend. This is an increase from Steris Plc’s previous quarterly dividend of $0.28. The ex-dividend date of this dividend was Friday, August 25th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.40%. Steris Plc’s dividend payout ratio is presently 88.57%.
In other news, Director Richard Martin Steeves sold 156,072 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $87.13, for a total value of $13,598,553.36. Following the sale, the director now owns 9,362 shares in the company, valued at $815,711.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael B. Wood sold 4,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $81.50, for a total value of $326,000.00. Following the completion of the sale, the director now owns 26,131 shares in the company, valued at approximately $2,129,676.50. The disclosure for this sale can be found here. Insiders sold 176,086 shares of company stock worth $15,297,621 in the last 90 days. Company insiders own 2.55% of the company’s stock.
STE has been the topic of a number of analyst reports. Wellington Shields cut Steris Plc from a “gradually accumulate” rating to a “hold” rating in a research report on Monday, June 5th. Zacks Investment Research raised Steris Plc from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. BidaskClub cut Steris Plc from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Raymond James Financial, Inc. lifted their price objective on Steris Plc from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $86.75.
Steris Plc Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Stock Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related stocks with our FREE daily email newsletter.